FAVEZELIMAB

UNII:	H1396W7D1H
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	FAVEZELIMAB
GSRS Full Record:	H1396W7D1H i

2231068-83-8
ANTI-LAG3 MONOCLONAL ANTIBODY MK-4280
FAVEZELIMAB [USAN]
Favezelimab
Favezelimab [WHO-DD]
Immunoglobulin G4 [227-proline], anti-(human lymphocyte activation gene-3) (human-Mus musculus monoclonal C88 γ4-chain), disulfide with human-Mus musculus monoclonal C88 κ-chain, dimer
Immunoglobulin G4-kappa, anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-446) [VH (Homo sapiens IGHV1-58*01 (85.6%) -(IGHD) -IGHJ1*01 (91.7%)) [8.8.12] (1-119) -Homo sapiens IGHG4*01 (CH1 (120-217), hinge 1-12 (218-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (120-446)], (133- 218')-disulfide with kappa light chain humanized (1'- 218') [V-KAPPA (Homo sapiens IGKV2D-29*01 (82.0%) -IGKJ4*01 (100%))[10.3.9] (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; dimer (225-225'':228-228'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
MAVEZELIMAB
MK-4280
MK4280
favezelimab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

FAVEZELIMAB

Synonyms and Mappings

Resources